Literature DB >> 2411028

Progression of stroke after arrival at hospital.

M Britton, A Rödén.   

Abstract

In order to investigate the frequency, extent and importance of progression of stroke symptoms after arrival at hospital, 402 consecutive patients were studied. Speech ability, extremity and facial pareses were evaluated and graded on four occasions during hospitalization. Deterioration was noted in 43% of the patients; it was fairly marked in 25%. The frequency among the few patients with cerebral haemorrhage was much the same as in those with infarction. Limb motor function was affected in most cases. Half of the progressions occurred within the first 24 h after admission. Patients with progression stayed longer in hospital, were more disabled at discharge and more often needed further institutional care than those without progression, although the initial dysfunction was similar in the two groups. No characteristics were found that would help to identify a risk of deterioration. Thus, progression of stroke symptoms after arrival at hospital is a common and serious problem, whose solution calls for vigorous research.

Entities:  

Mesh:

Year:  1985        PMID: 2411028     DOI: 10.1161/01.str.16.4.629

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  17 in total

1.  What change in the National Institutes of Health Stroke Scale should define neurologic deterioration in acute ischemic stroke?

Authors:  James E Siegler; Amelia K Boehme; Andre D Kumar; Michael A Gillette; Karen C Albright; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2012-06-21       Impact factor: 2.136

2.  Effects of ezetimibe and anticoagulant combined therapy on progressing stroke: a randomized, placebo-controlled study.

Authors:  Lan Yang; Pingping Zhao; Jing Zhao; Juan Wang; Lei Shi; Xiaopeng Wang
Journal:  J Neurol       Date:  2016-09-15       Impact factor: 4.849

3.  Time to Neurological Deterioration in Ischemic Stroke.

Authors:  James E Siegler; Karen C Albright; Alexander J George; Amelia K Boehme; Michael A Gillette; Andre D Kumar; Monica Aswani; Sheryl Martin-Schild
Journal:  Med Student Res J       Date:  2017

4.  Recent developments in the diagnosis and management of stroke.

Authors:  S Solomon
Journal:  Bull N Y Acad Med       Date:  1986-04

Review 5.  [Blood pressure and the brain].

Authors:  A Hartmann; S Moskau
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

6.  Infections present on admission compared with hospital-acquired infections in acute ischemic stroke patients.

Authors:  Amelia K Boehme; Andre D Kumar; Adrianne M Dorsey; James E Siegler; Monica S Aswani; Michael J Lyerly; Dominique J Monlezun; Alexander J George; Karen C Albright; Timothy M Beasley; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-08-15       Impact factor: 2.136

7.  Leukocytosis in patients with neurologic deterioration after acute ischemic stroke is associated with poor outcomes.

Authors:  Andre D Kumar; Amelia K Boehme; James E Siegler; Michael Gillette; Karen C Albright; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2012-09-30       Impact factor: 2.136

8.  Effect of lipid profile upon prognosis in ischemic and haemorrhagic cerebrovascular stroke.

Authors:  Anuradha Bharosay; Vivek V Bharosay; Debapriya Bandyopadhyay; Ajoy Sodani; Meena Varma; Haren Baruah
Journal:  Indian J Clin Biochem       Date:  2013-08-31

9.  Effect of upper airway obstruction in acute stroke on functional outcome at 6 months.

Authors:  P M Turkington; V Allgar; J Bamford; P Wanklyn; M W Elliott
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

10.  A proposal for the classification of etiologies of neurologic deterioration after acute ischemic stroke.

Authors:  James E Siegler; Amelia K Boehme; Karen C Albright; Alexander J George; Dominique J Monlezun; T Mark Beasley; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-07-16       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.